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Abstract: The lower urinary tract (LUT) comprises a storage unit, the urinary bladder, and an outlet, the urethra. The  
coordination between the two structures is tightly controlled by the nervous system and, therefore, LUT function is highly 
susceptible to injuries to the neuronal pathways involved in micturition control. These injuries may include lesions to the 
spinal cord or to nerve fibres and result in micturition dysfunction. A common trait of micturition pathologies, irrespective 
of its origin, is an upregulation in synthesis and secretion of neurotrophins, most notably Nerve Growth Factor (NGF) and 
Brain Derived Neurotrophic Factor (BDNF). These neurotrophins are produced by neuronal and non-neuronal cells and  
exert their effects upon binding to their high-affinity receptors abundantly expressed in the neuronal circuits regulating 
LUT function. In addition, NGF and BDNF are present in detectable amounts in the urine of patients suffering from  
various LUT pathologies, suggesting that analysis of urinary NGF and BDNF may serve as likely biomarkers to be  
studied in tandem with other factors when diagnosing patients. Studies with experimental models of bladder dysfunction 
using antagonists of NGF and BDNF receptors as well as scavenging agents suggest that those NTs may be key elements 
in the pathophysiology of bladder dysfunctions. In addition, available data indicates that NGF and BDNF might constitute 
future targets for designing new drugs for better treatment of bladder dysfunction. 
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INTRODUCTION 
  The lower urinary tract (LUT) is composed of the urinary 
bladder, essential storage unit, and the urethra that allows for 
urine elimination. The storage and periodic elimination of 
urine depend on the coordinated activity of those organs [1], 
which receive sensory (Adelta and C-fibres), parasympa-
thetic and sympathetic innervations. The strict control of 
LUT function is dependent on a set of on-off switching neu-
ronal circuits. During storage, the smooth and striated parts 
of the urethral sphincter receive excitatory sympathetic in-
put, preventing involuntary bladder emptying, whereas the 
parasympathetic innervation of the detrusor muscle of the 
bladder remains inhibited [2, 3]. Bladder contraction is initi-
ated upon activation of sensory mechanisms that detect a 
sudden increase in intravesical pressure. The parasympa-
thetic innervation is then activated, providing excitatory in-
put to the detrusor. At the same time, the sympathetic drive 
to the bladder neck and urethra is interrupted. As a result, the 
sphincter relaxes preceeding detrusor contraction, necessary 
to eliminate urine [1, 4]. In addition, supraspinal centres also 
contribute to regulation of bladder function, providing an-
other level of complexity to micturition control. Thus, it 
comes as no surprise that regulation of LUT function is sen-
sitive to a variety of injuries that jeopardize normal bladder 
control. Such injuries include infections and neuronal lesions 
(spinal cord injury, cerebrovascular accidents, Parkinson   
disease…) but, in some cases, are difficult to identify. One  
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common trait of bladder dysfunction, irrespective of its   
origin, is increased synthesis and release of NTs in urine   
and LUT tissue. 
NEUROTROPHINS (NTs) 
  Neurotrophins (NTs) are a well characterized family of 
growth factors playing important roles in survival, growth 
and differentiation of developing neuronal populations of the 
central and peripheral nervous systems [5-7]. In the adult, 
NTs may also contribute to the modulation of pre-existing 
synapses, thereby influencing synaptic transmission [6, 8]. 
The NTs family comprises several members, the most stud-
ied and discussed in the present review being Nerve Growth 
Factor (NGF) and Brain-Derived Neurotrophic Factor 
(BDNF). All NTs are synthesized as pro-molecules consti-
tuted by a pair of ,  and  subunits. Following synthesis 
and subsequent exocytosis, proneurotrophins suffer a prote-
olytic cleavage by extracellular proteases to form mature 
NTs, constituted exclusively by  subunits. This represents a 
mechanism that controls the specificity action of NTs [6]. It 
is traditionally accepted that NTs are synthesized and re-
leased by peripheral tissues and retrogradely transported   
to the soma of sensory neurons. This is the basis of the so-
called neurotrophic theory [9]. 
  NTs exert their effects upon binding to their low-affinity 
receptor p75
NTR or to their high-affinity tyrosine kinase (Trk) 
receptor [6, 10, 11]. Trk receptors are a family of cell surface 
transmembrane glycoproteins encoded by trk proto onco-
genes. These receptors have a similar structure: an intracellu-
lar tyrosine kinase domain, a short transmembranar sequence 
and an extracellular region containing a signal peptide, two 
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and two Ig-like domains. The second Ig-like domain is the 
major ligand-binding region and each Trk receptor has a 
different sequence which is specific for each ligand. The 
extracellular portions of the Trk receptors are less conserved 
than the intracellular domains, which accounts for the   
variability necessary for the specific recognition of each   
NT [12].  
  Trk receptors may be expressed as dimers, with or with-
out the presence of p75
NTR. If the ratio p75
NTR/Trk is high or 
if p75
NTR is expressed in the absence of Trk, binding of neu-
rotrophins may promote apoptosis [12, 13]. If the ratio 
p75
NTR/Trk is low, binding of tissue-derived neurotrophins to 
their specific Trk receptor will promote cell survival, among 
other cellular functions, by inducing downstream activation 
of different intracellular transduction pathways, such as   
ras-raf-MAPK, PI3K-Akt-GSKIII, PLC-DAG-PKC and 
S6kinase pathway [12, 14].  
NERVE GROWTH FACTOR (NGF)  
  NGF was the first member of the neurotrophin family to 
be described [15]. This NT may be synthesized by neurons 
and non-neuronal cells, including cells from the salivary 
glands [16, 17], epithelial [18-21] and mast cells [13]. NGF 
plays an essential role during the development of the periph-
eral nervous system, regulating the survival and function of 
postganglionic sympathetic neurons and small diameter pri-
mary afferents [6, 9, 22-24,]. In addition, several studies 
show that NGF is crucial for altered pain states [25-28]. Sen-
sory neurons responding to NGF belong to the small and 
medium diameter groups of sensory afferents. Upon binding 
to TrkA, its high-affinity receptor, NGF may induce the ex-
pression of several genes that code for various neurotrans-
mitters, receptors and voltage-gated ion channels [6, 29]. 
Examples of genes regulated by NGF include the ones cod-
ing for P2X3 (ATP receptor), ASIC 3 (Acid-sensitive ion 
channel 3), neuropeptides (such as Substance P and CGRP, 
Calcitonin gene-related peptide) and other neurotrophins 
(such as BDNF) [6, 30]. Thus, it is clear that NGF may in-
duce long-term alterations in the sensory system and may, 
therefore, contribute to long-lasting phenotypic changes oc-
curring during chronic painful conditions. NGF may also 
contribute to altered peripheral sensitivity by regulating post-
translational modification of pre-existent membrane recep-
tors, most notably Transient Receptor Potential Vanilloid 1 
(TRPV1) [31-33]. Interestingly, whereas post-translational 
events occur shortly after TrkA activation, NGF-mediated 
transcriptional control is likely to take many hours or even 
days, suggesting that the time span for NGF-induced events 
is broad.  
  NGF may also regulate peripheral sensitivity by modulat-
ing the crosstalk between TRPV1 with other receptors, 
namely cannabinoid receptor 1 (CB1), which has been 
shown to be co-expressed with TRPV1 in sensory neurons 
[34, 35, 36]. The endogenous cannabinoid anandamide has 
long been established as a CB1 agonist [37]. Its role as a 
TRPV1 agonist was established more recently [34, 36, 38]. 
In rats, exogenous application of anandamide to the bladder 
induced bladder overactivity and spinal expression of the 
pain evoked immediate early gene c-fos in a capsazepine, a 
TRPV1 antagonist, dependent manner [38]. In cultured sen-
sory neurons, it was shown that anandamide regulates CGRP 
release from TRPV1-expressing neurons [36]. Both studies 
demonstrated that blockade of CB1 potentiated the excitatory 
effects of anandamide [36, 38], suggesting that anandamide 
could have an excitatory effect via TRPV1 and an inhibitory 
one via CB1, mostly likely depending on its concentration. 
Indeed, while at low concentrations anandamide lead to a 
CB1-mediated inhibition of neuropeptide release, at higher 
concentration anandamide evoked the opposite in a TRPV1-
dependent fashion [39, 40]. NGF levels are critical for the 
imbalance between the excitatory and inhibitory effects of 
anandamide [41]. If levels of NGF are high, TRPV1 expres-
sion is upregulated and CB1 activation by anandamide po-
tentiates rather, than inhibits, Ca
2+ entry via  TRPV1 [41]. 
This is particularly relevant as in inflammatory conditions, 
such as cystitis, NGF levels increase and contributes to al-
tered pain states and bladder overactivity [6, 7]. The interac-
tion between NGF and CB1 could also occur in a direct 
manner, rather than via TRPV1. Indeed, CB1 was shown to 
co-localize with TrkA, although its expression does not seem 
to be mediated by NGF [35]. It was further demonstrated that 
NGF-induced thermal and visceral hyperalgesia were re-
duced by CB1 and CB2 activation by anandamide and en-
hanced following CB blockade [42-44]. Further studies are 
warranted to better understand the relation between cannabi-
noid signaling and NGF.  
NGF AND BLADDER OUTLET OBSTRUCTION 
  The first evidence suggesting a role for NGF in the LUT 
came from the pioneer studies of Steers and co-workers who 
studied the effects of bladder outlet obstruction (BOO) on 
NGF contents present in the urinary bladder. BOO is a 
highly common condition among men caused by benign 
prostatic hyperplasia. It has been shown that in human BOO 
patients, as well as in animals with obstructed urethras, the 
levels of NGF in the bladder were significantly increased 
[45]. In addition, following experimental BOO, bladder sen-
sory afferents were hypertrophied [45-47], a change accom-
panied by a peak in NGF concentration [45]. Interestingly, 
relief of obstruction lead to a partial reversal of neuronal 
hypertrophy and a decrease in the high NGF levels [45]. 
Moreover, the spinal expression of GAP-43, a known marker 
of axonal sprouting, was upregulated in BOO rats. This was 
not observed in NGF-immune rats, confirming the pivotal 
role of NGF in the morphological changes of sensory affer-
ents induced by BOO [48].  
NGF AND OVERACTIVE BLADDER (OAB) 
  The Overactive Bladder (OAB) syndrome is currently 
defined by the International Continence Society as urgency, 
with or without incontinence, usually with frequency and 
nocturia, in the absence of proven infection or other obvious 
pathology [49, 50]. OAB is a highly prevalent disorder that 
impacts the lives of millions of people worldwide, especially 
in older individuals. In fact, the prevalence of OAB symp-
toms in the population over 70 years old reaches 40%, which 
constitutes an important issue now that the life expectancy is 
higher [51]. Despite its high prevalence, most patients do not 
seek medical attention and are not aware that OAB is treat-
able.  
  The pathogenesis of OAB is still mostly unknown, and 
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than the cure [51]. However, it is accepted that the to patho-
physiology of OAB concurs physical injury to afferent path-
ways in the LUT and mechanisms such as increased afferent 
activity, decreased supraspinal inhibition and increased re-
lease of neurotransmitters [52]. Whatever the cause, it is 
accepted that urgency is the key symptom and driving force 
for OAB [53, 54]. However, objective grading of urgency 
symptoms is a difficult task and reports vary amongst pa-
tients. In most cases, it is possible to perform urodynamic 
studies that allow an unbiased detection of detrusor overac-
tivity. However, not all OAB patients present detrusor dys-
function which represents an increased difficulty when diag-
nosing and treating OAB patients. Thus, there is a great need 
for more accurate means to diagnose OAB and recent studies 
have focused on the detection of urinary biomarkers [55], 
most notably on urinary NGF. 
  Recent pilot clinical studies showed that urinary NGF 
levels are higher (approximately 12-fold) in patients with 
OAB than normal controls [56-59]. Although not correlating 
with the amount of NGF present in bladder tissue [19], uri-
nary levels of NGF can be used to differentiate patients with 
OAB wet and OAB dry, the concentrations being higher in 
the former group of patients [59]. In addition, urinary NGF 
concentration correlates with urgency intensity in OAB pa-
tients classified as measured by the Indevus urgency severity 
scale (USS) scores of 3 or 4 [57]. Successful antimuscarinic 
treatment reduces USS score and urinary NGF levels with a 
reversal occurring upon withdrawal of the therapy [58, 59]. 
In OAB patients refractory to antimuscarinics, botulinum 
toxin markedly reduces urinary NGF levels [60]. Urinary 
NGF is also increased in interstitial cystitis/bladder pain 
syndrome [60, 61]. In this condition, like in patients with 
neurogenic detrusor overactivity [62], successful treatment 
with botulinum toxin, which resulted in pain reduction, im-
proved quality of life and bladder function, lead to a signifi-
cant reduction in urinary NGF [60].  
  The importance of NGF in bladder function has been 
further demonstrated in a series of studies with experimental 
animals. In the urinary tract, NGF is produced by bladder 
smooth muscle and urothelium [28]. The majority of bladder 
sensory afferents projecting through the pelvic nerve express 
the TrkA receptor [23]. Using an experimental model of 
chronic bladder inflammation, it has been demonstrated that 
TrkA expression and activation is upregulated in bladder 
afferents during bladder inflammation and spinal cord injury 
[63, 64] in tandem with increased levels of NGF mRNA in 
the bladder [65]. NGF administration via  different routes 
resulted in bladder overactivity, characterized by reduction 
of bladder capacity and inter-contraction interval [66-69]. 
Likewise, reduction of NGF levels decrease the high fre-
quency of bladder contractions in animals with bladder in-
flammation [70, Frias et al., unpublished observations] and 
spinal cord injury [71, 72]. In what concerns visceral pain, 
the contribution of NGF to sensitize bladder afferents during 
inflammation has long been established [23, 73]. Thermal 
hyperalgesia associated with inflammation of the urinary 
bladder was also shown to be NGF-dependent [43, 44, 74]. 
In addition, treatment with cannabinoids or NGF sequestra-
tion reduced referred pain levels, confirming the importance 
of NGF in visceral pain and supporting an interaction be-
tween NGF and cannabinoid signalling [43, 44, 74, 75; Frias 
et al., unpublished results].  
BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) 
  BDNF is the most abundant NT although less investi-
gated at the present moment [76]. Like NGF, BDNF also 
contributes to the survival and proper function of sensory 
neurons [6, 77-79]. During the developmental period, BDNF 
is crucial for the development of cranial sensory neurons 
[80] as well as mechanoreceptors innervating the Meissner 
and Pacinian corpuscles and chemoreceptors innervating 
taste buds [80-82]. In the adult, BDNF is essential for neu-
ronal survival and seems to contribute to mechanosensation 
[83], possibly via ASIC2, an important mechanotransducer 
[84]. BDNF is constitutively expressed by small- and me-
dium-sized peptidergic neurons [5, 85, 86], but it is also pro-
duced by non-neuronal cells, including those present in the 
urinary bladder, lung and colon [87, 88]. This NT exerts its 
effects  via  its high affinity receptor, TrkB receptor, ex-
pressed in the central and peripheral nervous system. Along 
with its well established trophic effect on neuronal tissue 
[15] and its relevance in plasticity events (such as LTP in the 
hippocampus, [89]), the importance of BDNF in nociception 
has also been under investigation [90]. It has been shown 
that intraplantar administration of BDNF induces transient 
thermal hyperalgesia possibly by sensitizing peripheral sen-
sory neurons [91]. However, BDNF seems to be more 
prominent at central locations as it is anterogradely trans-
ported to the spinal cord, where it is released upon noxious 
peripheral stimulation [86]. BDNF is present in synaptic 
vesicals at central terminal endings of sensory fibres, co-
localizing with Substance P and CGRP [5]. Interestingly, 
BDNF expression is regulated by NGF and following pe-
ripheral inflammation, the levels of BDNF are upregulated in 
TrkA-expressing neurons [5, 6, 78, 90, 92]. BDNF release 
within the spinal cord leads to ERK phosphorylation [5, 6, 
78, 93] and PKC activation, important events for BDNF-
induced thermal hyperalgesia and tactile allodynia [5, 6, 63]. 
In addition, in the spinal cord BDNF modulates the glutama-
tergic neurotransmission in an ERK-dependent manner by 
increasing the phosphorylation of the NR1 subunit of the 
NMDA (N-methyl-D-aspartate) receptor [94, 95]. The im-
portance of BDNF in pain perception has been further estab-
lished by studies that abolish its downstream effects. It has 
been reported that administration of BDNF-scavenging pro-
teins (TrkB-IgG) or antisense oligodeoxynucleotides reduces 
pain-related behaviour in animals treated with formalin or 
carrageenan [92, 96].  
BDNF IN THE LUT 
  Little is known about the role of BDNF in bladder func-
tion both in normal and in pathological conditions and avail-
able studies are mostly confined to experimental models of 
bladder dysfunction. It has been demonstrated that following 
chronic bladder inflammation or spinal cord injury, the syn-
thesis of BDNF in the urinary bladder is strongly increased 
[65, 88]. Accordingly, the activation levels of TrkB, present 
in bladder sensory afferents, are upregulated in the same 
models [63, 64], suggesting that peripherally synthesized 
BDNF is uptaken by bladder afferents. The importance of 
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is still under debate. As for BDNF scavenging studies, those 
are very scarce. Nevertheless, a recent study from our group 
showed that BDNF sequestration improved bladder function 
in rats with chronic cystitis [88]. The same treatment did not 
produce any effects on bladder reflex activity of intact ani-
mals [88], suggesting that BDNF’s effect on bladder function 
seem to be restricted to pathological conditions. Ongoing 
work from our group has further demonstrated that BDNF 
seems to play its contribution at the central nervous system 
in detriment of peripheral effects (Frias et al., unpublished 
observations). In what concerns clinical data, only one study 
has evaluated BDNF in the urine of bladder pain syn-
drome/interstitial cystitis patients. In this study, the levels of 
urinary BDNF detected were increased but were significantly 
reduced after botulinum toxin administration [60]. 
CONCLUSION 
  In summary, experimental and clinical studies regarding 
the importance of NTs, NGF and BDNF in particular, in the 
lower urinary tract have obtained enough data to support a 
role of these NTs in LUT. More interestingly, the presence 
of NGF and BDNF in the urine of patients, the amounts of 
which correlate with the severity of LUT, and the variations 
observed after different treatments may indicate that urinary 
NTs could be new useful biomarkers to complement existent 
diagnostic tools. Experimental studies indicate that it is 
likely that NGF and BDNF may be key elements in the 
pathophysiology of bladder dysfunction. However, it is clear 
that data concerning the role of BDNF in the LUT is still 
scarce and more studies are warranted to clarify this. It is 
also necessary to fully establish if a) urinary NTs are reliable 
biomarkers of bladder dysfunction and if b) NTs are suitable 
therapeutic targets for bladder treatment. Future studies will 
certainly elucidate and establish the true function of NTs in 
the LUT in normal and pathological conditions and provide 
better means to diagnose and hopefully treat LUT. 
LIST OF ABBREVIATIONS 
ASIC =  Acid-sensitive  ion  channel 
BOO  =  Bladder outlet obstruction  
BDNF  =  Brain derived neurotrophic factor 
CGRP  =  Calcitonin gene-related peptide 
ERK  =  Extracellular signal-regulated kinase 
LUT  =  Lower urinary tract 
NGF  =  Nerve growth factor 
NMDA =  N-methyl-D-aspartate  receptor 
NTs =  Neurotrophins 
OAB =  Overactive  bladder 
Trk  =  Tyrosine kinase receptor 
TRPV1  =  Transient receptor potential vanilloid 1 
USS  =  Urgency severity scale 
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